Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
01 2022
Historique:
pubmed: 23 11 2021
medline: 15 2 2022
entrez: 22 11 2021
Statut: ppublish

Résumé

The incidence of pulmonary embolism has been increasing, but its case-fatality rate is decreasing, suggesting a lesser severity of illness. The clinical importance of patients with pulmonary embolism isolated to the subsegmental vessels is unknown. To determine the rate of recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation. Multicenter prospective cohort study. (ClinicalTrials.gov: NCT01455818). Eighteen sites between February 2011 and February 2021. Patients with isolated subsegmental pulmonary embolism. At diagnosis, patients underwent bilateral lower-extremity venous ultrasonography, which was repeated 1 week later if results were negative. Patients without deep venous thrombosis did not receive anticoagulant therapy. The primary outcome was recurrent venous thromboembolism during the 90-day follow-up period. Recruitment was stopped prematurely because the predefined stopping rule was met after 292 of a projected 300 patients were enrolled. Of the 266 patients included in the primary analysis, the primary outcome occurred in 8 patients, for a cumulative incidence of 3.1% (95% CI, 1.6% to 6.1%) over the 90-day follow-up. The incidence of recurrent venous thromboembolism was 2.1% (CI, 0.8% to 5.5%) and 5.7% (CI, 2.2% to 14.4%) over the 90-day follow-up in patients with single and multiple isolated subsegmental pulmonary embolism, respectively. No patients had a fatal recurrent pulmonary embolism. The study was restricted to patients with low-risk subsegmental pulmonary embolism. Overall, patients with subsegmental pulmonary embolism who did not have proximal deep venous thrombosis had a higher-than-expected rate of recurrent venous thromboembolism. Heart and Stroke Foundation of Canada and French Ministry of Health Programme Hospitalier de Recherche Clinique.

Sections du résumé

BACKGROUND
The incidence of pulmonary embolism has been increasing, but its case-fatality rate is decreasing, suggesting a lesser severity of illness. The clinical importance of patients with pulmonary embolism isolated to the subsegmental vessels is unknown.
OBJECTIVE
To determine the rate of recurrent venous thromboembolism in patients with subsegmental pulmonary embolism managed without anticoagulation.
DESIGN
Multicenter prospective cohort study. (ClinicalTrials.gov: NCT01455818).
SETTING
Eighteen sites between February 2011 and February 2021.
PATIENTS
Patients with isolated subsegmental pulmonary embolism.
INTERVENTION
At diagnosis, patients underwent bilateral lower-extremity venous ultrasonography, which was repeated 1 week later if results were negative. Patients without deep venous thrombosis did not receive anticoagulant therapy.
MEASUREMENTS
The primary outcome was recurrent venous thromboembolism during the 90-day follow-up period.
RESULTS
Recruitment was stopped prematurely because the predefined stopping rule was met after 292 of a projected 300 patients were enrolled. Of the 266 patients included in the primary analysis, the primary outcome occurred in 8 patients, for a cumulative incidence of 3.1% (95% CI, 1.6% to 6.1%) over the 90-day follow-up. The incidence of recurrent venous thromboembolism was 2.1% (CI, 0.8% to 5.5%) and 5.7% (CI, 2.2% to 14.4%) over the 90-day follow-up in patients with single and multiple isolated subsegmental pulmonary embolism, respectively. No patients had a fatal recurrent pulmonary embolism.
LIMITATION
The study was restricted to patients with low-risk subsegmental pulmonary embolism.
CONCLUSION
Overall, patients with subsegmental pulmonary embolism who did not have proximal deep venous thrombosis had a higher-than-expected rate of recurrent venous thromboembolism.
PRIMARY FUNDING SOURCE
Heart and Stroke Foundation of Canada and French Ministry of Health Programme Hospitalier de Recherche Clinique.

Identifiants

pubmed: 34807722
doi: 10.7326/M21-2981
doi:

Banques de données

ClinicalTrials.gov
['NCT01455818']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-35

Subventions

Organisme : CIHR
ID : CDT-142654
Pays : Canada

Investigateurs

Amin Zahrai (A)
Aurélien Delluc (A)
Lisa Duffett (L)
Lana Castellucci (L)
Alan Karovitch (A)
Cathy Code (C)
Dimitri Scarvelis (D)
Carol Gonsalves (C)
Melissa Forgie (M)
Esteban Gandara (E)
Mark Blostein (M)
Susan Kahn (S)
Vicky Tagalakis (V)
Maral Koolian (M)
Bruce Ritchie (B)
Sarah Takach-Lapner (S)
Jeffery Patterson (J)
Lori Rackel (L)
Alejandro Lazo-Langner (A)
Judith Kovacs (J)
Susan Solymoss (S)
Michelle Zondag (M)
Nicholas Forward (N)
Mary Margaret Keating (MM)
Sue Robinson (S)
David Anderson (D)
Ismail Sharif (I)
Andrea Kew (A)
David Macdonald (D)
Meissa Kare (M)
Amina Chaalal (A)
Thomas Moumneh (T)
Béatrice Gable (B)
Aurore Hamard (A)
Chloé Ragueneau (C)
Barbara Maquin (B)
Clotilde Aubert (C)
Cindy Augereau (C)
Dominique Mottier (D)
Emmanuelle Le Moigne (E)
Sophie Boismal (S)
Pauline Stephan (P)
Cloé Jezequel (C)
Raphael Le Mao (R)
Cécile Tromeur (C)
Claire de Moreuil (C)
Julien Coadic (J)
Christelle Camminada (C)
Marc Danguy Des Déserts (MD)
Elisabeth Beuvard (E)
Guy Meyer (G)
Benjamin Planquette (B)
Jean Pastre (J)
Gisèle Morin (G)
Alexis Ferré (A)
Amélie Marquette (A)
Siwar Smii (S)
Sandrine Accassat (S)
Carole Chauvet (C)
Corinne Bernabet (C)
Nadège Koffi Malan Antoine (NK)
Louise Riberdy (L)
Nick van Es (N)
Pieter Kamphuisen (P)
Peter Verhamme (P)
Jan-Beyer Westendorf (JB)
Philippe Girard (P)
Florence Parent (F)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Grégoire Le Gal (G)

Centre d'Investigation Clinique, Centre Hospitalier Régional et Universitaire de Brest, Brest, France, and Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (G.L.).

Michael J Kovacs (MJ)

Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada (M.J.K.).

Laurent Bertoletti (L)

Service de Médecine Vasculaire et Thérapeutique, Hôpital Nord, CHU de St-Etienne, INSERM, SAINBIOSE, U1059, Dysfonction Vasculaire et Hémostase et Université Jean-Monnet, CIC1408, F- 42055 Saint-Etienne, Réseau français F-CRIN INNOVTE, Saint-Etienne, France (L.B.).

Francis Couturaud (F)

Centre d'Investigation Clinique, Centre Hospitalier Régional et Universitaire de Brest, and Département de médecine interne, médecine vasculaire et pneumologie, Hôpital de la Cavale Blanche, EA3878-GETBO, Univ Brest, Réseau français F-CRIN INNOVTE, CHRU Brest, Brest, France (F.C.).

Carole Dennie (C)

Department of Radiology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (C.D., E.P.).

Andrew M Hirsch (AM)

Department of Medicine, McGill University, Jewish General Hospital, Montreal, Quebec, Canada (A.M.H.).

Menno V Huisman (MV)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Dutch Thrombosis Network, Leiden, the Netherlands (M.V.H., F.A.K.).

Frederikus A Klok (FA)

Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Dutch Thrombosis Network, Leiden, the Netherlands (M.V.H., F.A.K.).

Noémie Kraaijpoel (N)

Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands (N.K.).

Ranjeeta Mallick (R)

Ottawa Methods Center, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (R.M.).

Amanda Pecarskie (A)

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (A.P., P.P., P.W., M.C.).

Elena Pena (E)

Department of Radiology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (C.D., E.P.).

Penny Phillips (P)

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (A.P., P.P., P.W., M.C.).

Isabelle Pichon (I)

Service de Recherche Clinique, Hôpital d'Instruction des Armées, Brest, France (I.P.).

Tim Ramsay (T)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (T.R.).

Marc Righini (M)

Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland (M.R.).

Marc A Rodger (MA)

Department of Medicine, McGill University, McGill University Health Center, Montreal, Quebec, Canada (M.A.R.).

Pierre-Marie Roy (PM)

Univ Angers, MITOVASC, Equipe CarMe, Département de Médecine d'Urgence, Centre Hospitalier Universitaire d'Angers, Réseau français F-CRIN INNOVTE, Angers, France (P.R.).

Olivier Sanchez (O)

Université de Paris, Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, AP-HP.Centre - Université de Paris, INSERM UMR S 1140 Innovative therapies in hemostasis, Réseau français F-CRIN INNOVTE, Paris, France (O.S.).

Jeannot Schmidt (J)

Département de Médecine d'Urgence, Centre Hospitalier Universitaire Gabriel Montpied, Réseau français F-CRIN INNOVTE, Clermont-Ferrand, France (J.S.).

Sam Schulman (S)

Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada, and Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia (S.S.).

Sudeep Shivakumar (S)

Department of Medicine, Dalhousie University, Nova Scotia Health, Halifax, Nova Scotia, Canada (S.S.).

Albert Trinh-Duc (A)

Centre Hospitalier d'Agen-Nérac, Agen, France (A.T.).

Rachel Verdet (R)

Direction de la Recherche et de l'Innovation, Centre Hospitalier Régional Universitaire de Brest, Brest, France (R.V.).

Ulric Vinsonneau (U)

Department of Cardiology, Clermont Tonnerre Hospital of Military Training, Brest, France (U.V.).

Philip Wells (P)

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (A.P., P.P., P.W., M.C.).

Cynthia Wu (C)

Department of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada (C.W.).

Erik Yeo (E)

Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada (E.Y.).

Marc Carrier (M)

Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada (A.P., P.P., P.W., M.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH